New Delhi, Gland Pharma on Monday said it has received approval from the UK health regulator to market a generic drug used to treat breast cancer.
The company has received approval from the US Food and Drug Administration (USFDA) for Eribulin Mesylate Injection (0.5 mg/mL single dose vial), it said in a statement.
It added that the product is expected to receive first general approval in the market and the company expects to launch the product through its marketing partners in the near future.
According to IQVIA, product sales in the US during the 12 months ending February 2024 are estimated at approximately US$92 million.
The company said it is co-developing several complex injectables, including th product, with Orbicular Pharmaceutical Technologies Pvt Ltd.
Shares of Gland Pharma closed 5.59 per cent higher at Rs 1,853.25 on the BSE on Monday.
The company has received approval from the US Food and Drug Administration (USFDA) for Eribulin Mesylate Injection (0.5 mg/mL single dose vial), it said in a statement.
It added that the product is expected to receive first general approval in the market and the company expects to launch the product through its marketing partners in the near future.
According to IQVIA, product sales in the US during the 12 months ending February 2024 are estimated at approximately US$92 million.
The company said it is co-developing several complex injectables, including th product, with Orbicular Pharmaceutical Technologies Pvt Ltd.
Shares of Gland Pharma closed 5.59 per cent higher at Rs 1,853.25 on the BSE on Monday.
